News & Latest Announcements
Beyond the Usual Suspects: Why Your Site Selection Strategy is Broken
The oncology landscape presents a strange paradox: the number of available investigator sites has surged by nearly 50% in five years, yet performance has remained flat.…
Read article
Case Study: How an integrated strategy saved a cell therapy trial 18 months and over $50M
What would saving 18 months and over $50 million on your lead asset’s development plan mean for your company? For most emerging biotechs, it’s the difference…
Read article
ICH E6(R3) – A New Operating System for Clinical Trials
The finalization of the ICH E6(R3) Good Clinical Practice (GCP) guideline represents the most significant evolution in clinical trial management in a decade. For sponsors and…
Read article
Why Streamlined Submissions Don’t Guarantee Global Success
The Harmonization Paradox In the world of global oncology trials, a dangerous illusion has taken hold: the harmonization paradox. With the full implementation of the EU’s…
Read article
BIO 2026: Building Connections That Accelerate Development
BIO International Convention in San Diego was, once again, a truly bright event. For four days, professionals from every corner of the life sciences ecosystem came…
Read article
Accelsiors at Swiss Biotech Day 2026: Embracing a Reinvigorated Industry
Swiss Biotech Day once again proved its standing as a central European hub for innovation, bringing together over 3,500 registrants from 58 countries, 150+ exhibitors, 31…
Read article
Stop Auditing Everything: A 3-Tier Framework for EU AI Compliance
The EU AI Act is daunting. When you read the full text, it feels like you need a massive compliance department just to run a clinical trial. But…
Read article
The AI You Didn’t Buy: Why “Invisible” Algorithms Are the Real Risk in EU Trials
You didn’t commission a custom machine learning model. You didn’t sign a contract for “High-Risk AI.” So, you assume your upcoming EU study is safe from the new EU AI…
Read article
The Safety Gap: Why CAR-T Trials in MS Require the 2024 McDonald Criteria & R3 Governance
Precision & Potency: The Future of Neuro-Immunology Aligning the diagnostic safety of McDonald 2024 with the therapeutic power of CAR-T. The High-Stakes Era of Neuro-Immunology For decades, Multiple Sclerosis…
Read article